Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.

Key facts

Study ID

NCT03880253

Run by

Concert Pharmaceuticals

People needed

30

Starts

2019-04-10

Expected to finish

2019-05-16

Last updated by the study team

2019-06-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult males and females between 18 and 55 years of age, inclusive
• Body weight ≥ 55 kg and body mass index within the range of 18 to 32 kg/m2, inclusive

You may not qualify if…

• Screening laboratory measurements outside the normal range associated with potential risk for the treatment under investigation at screening and/or prior to the first dose of study drug
• Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen or hepatitis C virus antibody
• History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal (GI) conditions
• Positive drug or alcohol test at screening or prior to the first dose of study drug

Where it is running

• Collaborative Neuroscience Network, LLC — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.